- Cancer Antibodies
- Metabolism Antibodies
- New Antibodies
- Crown Antibodies
- Secondary Antibodies
- Stem Cells
- Neurodegeneration >
- Goat Antibodies
- GPCR Antibodies
- Infectious Disease and Small Molecules
- Loading Control Antibodies
- Tag Antibody
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Biological Process >
- FL cDNA Clones
ZFYVE27 Antibody (N-term)
Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
United StatesOrdering Information
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanKoreaLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamOthers
|Catalog #||Size||Availability||Available Date|
(40 western blots)
|Backorder||4 months||DISCONTINUED INQUIRE CLICK Add to cart|
(8 western blots)
|Backorder||4 months||DISCONTINED INQUIRE CLICK Add to cart|
- Citations : 0
ZFYVE27 Antibody (N-term) - Product Information
|Other Accession||Q6P7B7, Q3TXX3, NP_001002261.1, NP_001002262.1|
|Calculated MW||45843 Da|
|Antigen Region||28-56 aa|
ZFYVE27 Antibody (N-term) - Additional Information
|Gene ID 118813|
ZFYVE27; Protrudin; Zinc finger FYVE domain-containing protein 27
This ZFYVE27 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 28-56 amino acids from the N-terminal region of human ZFYVE27.
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
ZFYVE27 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.
ZFYVE27 Antibody (N-term) - Protein Information
Functions as an upstream inhibitor of RAB11, regulating directional protein transport to the forming neurites. Involved in nerve growth factor-induced neurite formation. May have a more general role in cell projections formation.
Recycling endosome membrane; Multi-pass membrane protein. Endoplasmic reticulum membrane; Multi-pass membrane protein. Cell projection, growth cone membrane; Multi- pass membrane protein. Cell membrane; Multi-pass membrane protein Note=Localizes at both dendrites and axons.
ZFYVE27 Antibody (N-term) - Related Products
ZFYVE27 Antibody (N-term) - Research Areas
ZFYVE27 Antibody (N-term) (Cat. #AP17130a) western blot analysis in Jurkat cell line lysates (35ug/lane).This demonstrates the ZFYVE27 antibody detected the ZFYVE27 protein (arrow).
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a protein with several transmembrane domains, a Rab11-binding domain and a lipid-binding FYVE finger domain. The encoded protein appears to promote neurite formation. A mutation in this gene has been reported to be associated with hereditary spastic paraplegia, however the pathogenicity of the mutation, which may simply represent a polymorphism, is unclear.
Saita, S., et al. J. Biol. Chem. 284(20):13766-13777(2009)
Martignoni, M., et al. Am. J. Hum. Genet. 83(1):127-128(2008)
Shirane, M., et al. Science 314(5800):818-821(2006)
Mannan, A.U., et al. Am. J. Hum. Genet. 79(2):351-357(2006)
Wang, A.G., et al. Biochem. Biophys. Res. Commun. 345(3):1022-1032(2006)